t-cell-engager
(3)
Prolium Bioscience
Prolium Bioscience is a New York-based, clinical-stage biotechnology company developing PRO-203, a bispecific CD20xCD3 T-cell engager designed to deplete disease-driving B cells as an off-the-shelf therapy for severe autoimmune diseases, starting with systemic sclerosis and lupus. Founded in 2025 and backed by RTW Investments, the company in-licensed global non-oncology and ex-Asia oncology rights to the antibody from China's InnoCare Pharma and KeyMed Biosciences, and launched publicly in March 2026 with a $50 million Series A alongside first-patient dosing.
Vibrant Therapeutics
Vibrant Therapeutics (VibrantX) is a clinical-stage biotechnology company building intelligent, logic-gated antibody therapeutics that switch on only inside diseased tissue. By pairing computational protein design with high-throughput wet-lab validation across its BumbleBee, LogicBee and NeuroBee platforms, Vibrant develops conditionally activated, multi-specific antibody prodrugs for oncology, autoimmune, inflammatory and neurological diseases. Its lead program, VIB305, is a logic-gated masked T-cell engager for EGFR-positive solid tumors that has received FDA IND acceptance.
Normunity
Normunity is a clinical-stage biotech building a new class of cancer drugs it calls 'immune normalizers' - antibodies and T cell engagers that target previously hidden mechanisms tumors use to evade the immune system. Founded on the science of Yale immunologist Lieping Chen and led by drug-development veteran Rachel Humphrey, the company runs research at Yale's West Campus in West Haven, Connecticut, and dosed its first patient in 2025.